Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

124.70 -1.73 (-1.36%)

Streaming Delayed Price Updated: 3:43 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead ↗

November 28, 2022

Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.

Via Talk Markets

The 10 Most Shorted ETFs: Which Sectors Saw Short Interest Increase? ↗

November 22, 2022

Investors often short stocks to hedge positions against long positions or as a way to bet against a particular company. Benzinga provides a look at the most shorted stocks here.

Via Benzinga

Choppy Days Lie Ahead So Why Fight The Fed? ↗

October 10, 2022

We are in a bear market with choppy days over the next few months.

Via Talk Markets

My 3 Top Biotech Stock Picks for 2023 ↗

November 22, 2022

Biotech stocks are set to shine in 2023.

Via The Motley Fool

Stocks Drop On November 17 As The Dollar Moves Higher ↗

November 17, 2022

Stocks dropped as the dollar pushed higher ahead of options expiration.

Via Talk Markets

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗

November 09, 2022

Biotech stocks were hammered Wednesday, including several that had good news.

Via Investor's Business Daily

2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter ↗

November 06, 2022

These two healthcare stocks could deliver market-crushing gains by year's end.

Via The Motley Fool

What To Watch In The S&P Biotech ETF After Johnson & Johnson's $16.6B Abiomed Deal ↗

November 01, 2022

As the exodus out of mega-cap technology stocks continues, investors and money managers are looking for other sectors to rotate into.

Via Benzinga

Can Biotech Stocks Continue Rallying In This Bear Market? ↗

October 31, 2022

Via Talk Markets

This Beaten-Down ETF Is Still a Screaming Bear-Market Buy ↗

October 21, 2022

Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.

Via The Motley Fool

Steady As She Goes With Healthcare Stocks ↗

October 17, 2022

Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.

Via Talk Markets

My 3 Biggest Stock Market Predictions for October ↗

October 11, 2022

Now's not the best time to bet the farm on anything other than more uncertainty coming up.

Via The Motley Fool

Stocks May Be Nearing A Breaking Point ↗

September 27, 2022

We are seeing high yield spreads widen, and looking at the ratio of the SHY to HYG; it is clear that we surpassed the June highs.

Via Talk Markets

Can Healthcare Stocks Continue To Outperform? ↗

September 26, 2022

Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.

Via Talk Markets

Rare Economic/Technical Signal Has Only Flashed 9 Times In Last 54 Years ↗

September 24, 2022

A rare stock market signal combining technical and economic data was recently flashed. What can we learn from history regarding stock market/recession probabilities?

Via Talk Markets

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗

September 19, 2022

The biotech run off a June bottom is great — until you realize you could've netted more.

Via Investor's Business Daily

The Three Best Anti-Aging Stocks to Buy in September ↗

September 19, 2022

These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments

Via InvestorPlace

Biotech Stocks Stand to Benefit as Biden Announces Support for Industry ↗

September 12, 2022

President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks.

Via InvestorPlace

5 Monster Stock Market Predictions For The Week Of Sept. 12 ↗

September 11, 2022

This week will be interesting, with inflation data Tuesday and Wednesday. There will be a lot of Treasury auctions this week, which will move yields and stocks. The one wrinkle is that the VIX options...

Via Talk Markets

Stocks Drop On August 6 As Financial Conditions Tightening More ↗

September 06, 2022

Today’s battle for the S&P 500 was between 3,900 and 3,920. Right now, the index is just consolidating and is likely to drop to around 3,820 over the near term to fill the gap at that level.

Via Talk Markets

REITs And Utilities Show Glimmer As The S&P Wilts ↗

September 06, 2022

The S&P 500 failed to close below last Thursday's low as Utilities and REITs were bid.

Via Talk Markets

Healthcare Sector Still Looks Good But Lacks Momentum ↗

September 06, 2022

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...

Via Talk Markets

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Whither Small Caps After Fed’s Tough Talk? ↗

August 29, 2022

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...

Via Talk Markets

3 Investing Themes For The Next 3 Years ↗

August 25, 2022

With all of the noise about Jackson Hole tomorrow and whether they will be hawkish, dovish, pivot or not, we wanted to take a step back and think about broad themes we are/will be pursuing over the...

Via Talk Markets

“Wrong Side Of The Wave” Stock Market (And Sentiment Results) ↗

August 17, 2022

Spreads peaked at 6% in early July and have now rolled over to 4.24% (176 bps) in the past 5 weeks alone. This looks more like a small “aftershock” than a new earthquake.

Via Talk Markets

Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation? ↗

August 15, 2022

The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...

Via Talk Markets

Exploding Interest Rates May Finally Suck Stocks Lower ↗

August 11, 2022

Stocks moved lower today, despite moving sharply higher to start.

Via Talk Markets

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.